Current position

Ray Dalio’s Ge Healthcare Technologies I (GEHC) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ1 2024Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares162.67KHighest verified quarter-end share count
Quarters reported10Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Ge Healthcare Technologies I in Q1 2024. The reported position was increased and reduced across later filings. Bridgewater Associates, LP currently reports 15.60K shares. The latest verified filing showed: Sold 78.3% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 78.3% of the position−56.22K shares · 15.60K shares remained
Filing context

Quarter-end price $64.01 · Estimated holding basis $73.01

Q1 2026
Bought 395.9% more+57.33K shares · 71.81K shares reported after the change
Filing context

Quarter-end price $71.18 · Estimated holding basis $73.01

Q4 2025
Sold 4.6% of the position−696 shares · 14.48K shares remained
Filing context

Quarter-end price $82.02 · Estimated holding basis $80.26

Q3 2025
Bought 0.7% more+112 shares · 15.18K shares reported after the change
Filing context

Quarter-end price $75.10 · Estimated holding basis $80.26

Q2 2025
Sold 88.1% of the position−112.00K shares · 15.07K shares remained
Filing context

Quarter-end price $74.07 · Estimated holding basis $80.30

Q1 2025
Bought 296.8% more+95.04K shares · 127.06K shares reported after the change
Filing context

Quarter-end price $80.71 · Estimated holding basis $80.30

Portfolio importance

How important is Ge Healthcare Technologies I in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q2 2026
Current rank#838of 997 reported positions
Peak portfolio weight0.1%Q2 2024
Best historical rank#216Q2 2024
At peak importanceQ2 2024
GEHC
0.1%
Largest holding
6.0%
Cross-investor discovery

Who else owns Ge Healthcare Technologies I?

Also reported by 3 other tracked investors in their latest verified filings.

Nelson PeltzTrian Fund Management
GEHC4.7% of reported portfolio
Joel GreenblattGotham Asset Management
GEHC0.1% of reported portfolio
Christopher BloomstranSemper Augustus Investments Group LLC
GEHC0.0% of reported portfolio
Explore Ge Healthcare Technologies I across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$64.132026-09-18

Market context only; not an investor transaction price.

Latest filing quarter-end price$64.01Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$73.01Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.